International Cancer Institute

Cancer Care, Research, & Training

Home Sickle Cell Disease Clinical Trials

Sickle Cell Disease Clinical Trials

International Cancer Institute runs several clinical trials that target patients with sickle cell disease. The trials provide patients with alternative medicine for their disease and are a great way to help expand knowledge and help future patients.


Check the sickle cell clinical trials below to see if you qualify for any of them. 

Inclusion criteria for participating in the study

To participate in our sickle cell clinical trials, patients you should satisfy the following conditions

  • A diagnosis-proven by hemoglobin electrophoresis
  • Have at least 3 vaso-occlusive crises in the last 12 months that required hospital admissions or health care professional’s intervention with parenteral medications.
  • Should be at least 16 years of age
  • If using hydroxyurea, one must be on a stable dose for at least 6 months


If you are not using hydroxyurea, you can still come for assessment at the ICI Clinical Research Unit to see if you are a potential candidate for the ongoing studies

Ongoing clinical sickle cell clinical trials at ICI

  • A randomized, double-blind, placebo-controlled, multicenter study to assess the safety and efficacy of Inclacumab in participants with Sickle Cell Disease experiencing vaso-occlusive crises (GBT 131).
  • A randomized, double-blind, placebo-controlled, multicenter study of a single dose of Inclacumab to reduce re-admission in participants with sickle cell disease and recurrent vaso-occlusive crises (GBT 132).
  • An open-label extension study to evaluate the long-term safety of Inclacumab administered to participants with Sickle Cell Disease who have participated in an Inclacumab clinical trial (GBT 133).
  • A phase IIa randomized, double-blind, placebo-controlled study to characterize the pharmacokinetics and pharmacodynamics of Rifaximin novel formulations in patients with Sickle Cell Disease (RBSC 2161).
  • A Phase 1b Randomized, Placebo-Controlled Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Patients with Sickle Cell Disease.
  • A Randomized double-blind Phase IIa Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as adjunct Treatment in Prevention of Vaso-Occlusive episodes (VOE) in Sickle Cell Disease (SCD).


Why should you participate in ICI sickle trials?

Clinical trials present a unique opportunity to take new medication that may not be accessible anywhere else. Some of the reasons you may want to participate in ICI sickle cell disease clinical trials include:

  • Additional treatment options for vaso-occlusive crises
  • Ensure equity and diversity in clinical trials
  • Potentially improved outcomes
  • Add to the scientific knowledge of cancers
  • Access to cutting-edge drugs

Joining the sickle cell disease trials at International Cancer Institute

At ICI we prioritize patient care through out our programs. We ensure all our patients get the best services and access to the most effective drugs. 


If you are interested in taking part in our sickle cell clinical trials. Please write to us at or call +254 768 616 668

Opening Hours

Monday – Friday 8.00 – 17.00
Weekends Closed
Holidays Closed

Research Contacts

  • Address P.O. Box 8088-30100, Nandi Rd., Eldoret
  • Phone +254 718 473 446